Immunomodulation of Innate Immune Responses by Vasoactive Intestinal Peptide (VIP): Its Therapeutic Potential in Inflammatory Disease

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2009 Jul 17

PMID 19604262

Citations 22

Authors

S G R Smalley

P A Barrow

N Foster

Affiliations

Soon will be listed here.

Abstract

Since the late 1970s a number of laboratories have studied the role of vasoactive intestinal peptide (VIP) in inflammation and immunity. These studies have highlighted the dramatic effect of VIP on immune cell activation and function, and studies using animal models of disease have indicated that VIP has significant therapeutic and prophylactic potential. This review will focus on the effects of VIP on innate immune cell function and discuss the therapeutic potential for VIP in inflammatory diseases of humans.

Citing Articles

Ligands for Intestinal Intraepithelial T Lymphocytes in Health and Disease.

Hada A, Xiao Z Pathogens. 2025; 14(2).

PMID: 40005486 PMC: 11858322. DOI: 10.3390/pathogens14020109.

Gene Expression Analysis Links Autocrine Vasoactive Intestinal Peptide and ZEB1 in Gastrointestinal Cancers.

Rao I, Waller E, Dhamsania R, Chandrasekaran S Cancers (Basel). 2023; 15(13).

PMID: 37444395 PMC: 10340472. DOI: 10.3390/cancers15133284.

Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.

Ravindranathan S, Passang T, Li J, Wang S, Dhamsania R, Ware M Nat Commun. 2022; 13(1):6418.

PMID: 36302761 PMC: 9613684. DOI: 10.1038/s41467-022-34242-4.

Immunomodulatory Role of Neuropeptides in the Cornea.

Puri S, Kenyon B, Hamrah P Biomedicines. 2022; 10(8).

PMID: 36009532 PMC: 9406019. DOI: 10.3390/biomedicines10081985.

Progress in the mechanism and targeted drug therapy for COPD.

Wang C, Zhou J, Wang J, Li S, Fukunaga A, Yodoi J Signal Transduct Target Ther. 2020; 5(1):248.

PMID: 33110061 PMC: 7588592. DOI: 10.1038/s41392-020-00345-x.

References

Kim W, Kan Y, Ganea D, Hart R, Gozes I, Jonakait G . Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J Neurosci. 2000; 20(10):3622-30. PMC: 6772690. View

Mackenzie C, Lutz E, McCulloch D, Mitchell R, Harmar A . Phospholipase C activation by VIP1 and VIP2 receptors expressed in COS 7 cells involves a pertussis toxin-sensitive mechanism. Ann N Y Acad Sci. 1996; 805:579-84. DOI: 10.1111/j.1749-6632.1996.tb17523.x. View

Campbell R, Scanes C . Evolution of the growth hormone-releasing factor (GRF) family of peptides. Growth Regul. 1992; 2(4):175-91. View

Hajos F, Stark B, Hensler S, Prassl R, Mosgoeller W . Inhalable liposomal formulation for vasoactive intestinal peptide. Int J Pharm. 2008; 357(1-2):286-94. DOI: 10.1016/j.ijpharm.2008.01.046. View

Foster N, Hulme S, Barrow P . Vasoactive intestinal peptide (VIP) prevents killing of virulent and phoP mutant Salmonella typhimurium by inhibiting IFN-gamma stimulated NADPH oxidative pathways in murine macrophages. Cytokine. 2006; 36(3-4):134-40. DOI: 10.1016/j.cyto.2006.11.005. View

ODorisio M, ODorisio T, Cataland S, Balcerzak S . Vasoactive intestinal polypeptide as a biochemical marker for polymorphonuclear leukocytes. J Lab Clin Med. 1980; 96(4):666-72. View

Gonzalez-Rey E, Delgado M . Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology. 2006; 131(6):1799-811. DOI: 10.1053/j.gastro.2006.10.023. View

Arranz A, Abad C, Juarranz Y, Leceta J, Martinez C, Gomariz R . Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation. 2008; 15(1):46-53. DOI: 10.1159/000135623. View

Foster N, Andreadou K, Jamieson L, Preshaw P, Taylor J . VIP inhibits P. gingivalis LPS-induced IL-18 and IL-18BPa in monocytes. J Dent Res. 2007; 86(9):883-7. DOI: 10.1177/154405910708600915. View

10.

Foster N, Lea S, Preshaw P, Taylor J . Pivotal advance: vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. J Leukoc Biol. 2006; 81(4):893-903. DOI: 10.1189/jlb.0206086. View

11.

Gololobov G, Noda Y, Sherman S, Rubinstein I, Baranowska-Kortylewicz J, Paul S . Stabilization of vasoactive intestinal peptide by lipids. J Pharmacol Exp Ther. 1998; 285(2):753-8. View

12.

Foster N, Cheetham J, Taylor J, Preshaw P . VIP Inhibits Porphyromonas gingivalis LPS-induced immune responses in human monocytes. J Dent Res. 2005; 84(11):999-1004. DOI: 10.1177/154405910508401106. View

13.

Salomon R, Couvineau A, Voisin T, Lavallee D, Blais A, Darmoul D . Characterization of a common VIP-PACAP receptor in human small intestinal epithelium. Am J Physiol. 1993; 264(2 Pt 1):E294-300. DOI: 10.1152/ajpendo.1993.264.2.E294. View

14.

Gomariz R, Arranz A, Abad C, Torroba M, Martinez C, Rosignoli F . Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J Leukoc Biol. 2005; 78(2):491-502. DOI: 10.1189/jlb.1004564. View

15.

Boissard C, Marie J, Hejblum G, Gespach C, Rosselin G . Vasoactive intestinal peptide receptor regulation and reversible desensitization in human colonic carcinoma cells in culture. Cancer Res. 1986; 46(9):4406-13. View

16.

Thwaites D, Young J, Thorndyke M, Dimaline R . The isolation and chemical characterization of a novel vasoactive intestinal peptide-related peptide from a teleost fish, the cod, Gadus morhua. Biochim Biophys Acta. 1989; 999(2):217-20. DOI: 10.1016/0167-4838(89)90221-5. View

17.

Delgado M, Pozo D, Martinez C, Leceta J, Calvo J, Ganea D . Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol. 1999; 162(4):2358-67. View

18.

Delgado M, Munoz-Elias E, Gomariz R, Ganea D . Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol. 1999; 162(3):1707-16. View

19.

Said S, Mutt V . Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur J Biochem. 1972; 28(2):199-204. DOI: 10.1111/j.1432-1033.1972.tb01903.x. View

20.

Inaba K, Steinman R . Protein-specific helper T-lymphocyte formation initiated by dendritic cells. Science. 1985; 229(4712):475-9. DOI: 10.1126/science.3160115. View